Jeffrey B. Kindler
- Independent Director
- Director since 2017
Committees
- Chair, Talent & Compensation
Experience
- 2020 - Present Venture Partner, Artis Ventures, venture fund focused on life-sciences companies.
- 2020 - Present Senior Advisor, Blackstone Group, the world's largest alternative asset manager.
- 2013 - Present CEO, Centrexion Corporation, a biopharmaceutical company.
Other Public Company Directorships
- May 2024 – Present Lupin Pharmaceuticals (INE326A01037)
- 2021 - Present Terns Pharmaceutical (NASDAQ: TERN)
- 2012 - Present Precigen (NASDAQ: PGEN)
- 2017 - 2021 PPD (NASDAQ: PPD)
- 2015 - 2020 vTv Therapeutics (NYSE: VTVT)
- 2013 - 2020 Siga Technologies (NYSE: SIGA)
Notable Experience and Key Skill Sets
- Mr. Kindler is an experienced healthcare executive, investor and advisor who has held leadership positions at some of the world's most recognized companies including General Electric, McDonald's, and Pfizer where he served as Chairman and Chief Executive Officer.
- He brings substantial expertise in the pharmaceutical, healthcare and retail sectors to the Board.
- Mr. Kindler has a deep understanding of multinational corporate matters including regulation, litigation, compliance, crisis management, brand, franchise management, executive leadership and mergers and acquisitions.